Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

GT Everson, KD Sims, M Rodriguez-Torres, Christophe HEZODE, E Lawitz, M Bourliere, V Loustaud-Ratti, V Rustgi, H Schwartz, H Tatum, P Marcellin, S Pol, PJ Thuluvath, T Eley, X Wang, SP Huang, F McPhee, M Wind-Rotolo, E Chung, C Pasquinelli, DM Grasela, DF Gardiner,

Gastroenterology 01/02/2014;146(2) : 420-429 10.1053/j.gastro.2013.10.057 30/10/2013

Reply to: From the CUPIC study: great times are not coming (?).

F Carrat, Y Barthe, Christophe HEZODE, H Fontaine, JP Bronowicki,

J Hepatol. 01/01/2014;60(1) : 235-236 10.1016/j.jhep.2013.09.025 04/10/2013

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

F Poordad, E Lawitz, KR Reddy, NH Afdhal, Christophe HEZODE, S Zeuzem, SS Lee, JL Calleja, RS Jr Brown, A Craxi, H Wedemeyer, L Nyberg, DR Nelson, L Rossaro, LA Balart, TR Morgan, BR Bacon, SL Flamm, KV Kowdley, W Deng, KJ Koury, LD Pedicone, FJ Dutko, MH Burroughs, K Alves, J Wahl, CA Brass, JK Albrecht, MS Sulkowski,

Gastroenterology 01/11/2013;145(5) : 1035-1044.e5 10.1053/j.gastro.2013.07.051 04/08/2013

Management of anaemia and other treatment complications.

Christophe HEZODE,

Dig Liver Dis 30/09/2013;45 Suppl 5 : S337-S342 10.1016/j.dld.2013.07.010.

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

Christophe HEZODE, H Fontaine, C Dorival, D Larrey, F Zoulim, V Canva, V De Ledinghen, T Poynard, D Samuel, M Bourliere, JP Zarski, JJ Raabe, L Alric, P Marcellin, G Riachi, PH Bernard, V Loustaud-Ratti, S Metivier, A Tran, L Serfaty, A Abergel, X Causse, V Di Martino, D Guyader, D Lucidarme, V Grando-Lemaire, P Hillon, Cyrille FERAY, T Dao, P Cacoub, I Rosa, P Attali, V Petrov-Sanchez, Y Barthe, Jean-Michel PAWLOTSKY, S Pol, F Carrat, JP Bronowicki,

J Hepatol 01/09/2013;59(3) : 434-441 10.1016/j.jhep.2013.04.035 10/05/2013

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.

Stephane CHEVALIEZ, Christophe HEZODE, S Bahrami, M Grare, Jean-Michel PAWLOTSKY,

J Hepatol. 01/04/2013;58(4) : 676-683 10.1016/j.jhep.2012.11.039. 03/12/2012

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

M Bourliere, A Wendt, H Fontaine, Christophe HEZODE, S Pol, JP Bronowicki,

Liver Int 01/02/2013;33 Suppl 1 : 46-55 10.1111/liv.12067.

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

JP Bronowicki, S Pol, PJ Thuluvath, D Larrey, CT Martorell, VK Rustgi, DW Morris, Z Younes, MW Fried, M Bourliere, Christophe HEZODE, KR Reddy, O Massoud, GA Abrams, V Ratziu, B He, T Eley, A Ahmad, D Cohen, R Hindes, F McPhee, B Reilly, P Mendez, E Hughes,

Antivir Ther. 01/01/2013;18(7) : 885-8896 10.3851/IMP2660. 26/06/2013

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

SL Flamm, E Lawitz, I Jacobson, M Bourliere, Christophe HEZODE, JM Vierling, BR Bacon, C Niederau, M Sherman, V Goteti, HL Sings, RO Barnard, JA Howe, LD Pedicone, MH Burroughs, CA Brass, JK Albrecht, F Poordad,

Clin Gastroenterol Hepatol. 01/01/2013;11(1) : 81-87.e4; quiz e5 10.1016/j.cgh.2012.10.006. 10/10/2012